PA-PALLADIO-BIOSCIENCES
25.9.2020 12:11:11 CEST | Business Wire | Press release
Palladio Biosciences, Inc. (Palladio), a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the completion of a $20 million Series B investment. The financing was led by new investor, Samsara BioCapital, with participation from new investor, the Roche Venture Fund and existing investors, Medicxi and Osage University Partners. Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations.
Srinivas Akkaraju M.D, Ph.D, Managing General Partner of Samsara BioCapital, stated, "We are very excited about our investment in Palladio to support the development of lixivaptan, a drug that has the potential to deliver a meaningful therapeutic advancement in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The ALERT Study is an important step in assessing the safety differential of lixivaptan.”
“We are very pleased that Samsara and the Roche Venture Fund recognize the opportunity lixivaptan represents to patients suffering from ADPKD, and we are glad to be working with these new partners to further develop this important therapy,” said Francesco De Rubertis, co-founder and Partner at Medicxi.
Alex Martin, Chief Executive Officer of Palladio, added, "We are focused on developing our lead candidate, lixivaptan, for the treatment of ADPKD, an orphan disease with a significant unmet medical need that can impact many generations of a family. This Series B financing will fund our ALERT Study, a Phase 3 trial designed to assess the safety of lixivaptan in ADPKD patients who showed liver chemistry abnormalities or other signs of liver toxicity while taking tolvaptan, the only drug currently approved in the United States for the treatment of ADPKD. We are grateful for the support of the investment community in helping us advance this potential new drug and we welcome Samsara and the Roche Venture Fund to Palladio.”
Palladio is currently enrolling ADPKD patients into The ALERT Study (PA-ADPKD-303), the Company’s first Phase 3 clinical trial for lixivaptan. In this study, ADPKD patients between the ages of 18-65, who had been permanently discontinued from tolvaptan therapy due to liver chemistry abnormalities or other signs of liver toxicity, will be treated with lixivaptan for up to 58 weeks. The primary objective of the study is to determine the liver safety of lixivaptan in these patients. Visit Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT) for more information.
About Palladio Biosciences, Inc.
Palladio Biosciences is a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. Palladio is developing its lead drug, lixivaptan, for Autosomal Dominant Polycystic Kidney Disease (ADPKD), an orphan kidney disease for which there are limited treatment options. Lixivaptan is a potent, selective vasopressin V2 receptor antagonist, a mechanism of action that has clinical proof of concept to slow kidney function decline in adults at risk of rapidly progressing ADPKD. It has successfully completed a Phase 2 clinical trial, The ELiSA Study, in patients with ADPKD, and has also been successfully administered to a patient who had previously been unable to take tolvaptan due to liver enzyme increases under an expanded access program. Lixivaptan is for investigational use only. For more information, please visit our website at Palladio .
Polycystic Kidney Disease (PKD) Key Facts and Figures
PKD is an inherited genetic disease that affects up to 600,000 people in the United States and millions globally. It is estimated that approximately 140,000 people in the United States have been diagnosed with ADPKD, the most common type of PKD. A person with ADPKD has a 50 percent chance of passing the disease on to each of his or her children. The disease is characterized by uncontrolled growth of fluid-filled cysts in the kidney, which can each grow to be as large as a football. Symptoms often include kidney infections and pain. The continued enlargement of cysts and replacement of normal kidney tissue causes irreversible loss of renal function. Every year there are approximately 2,500 new PKD patients in the United States who require dialysis or a kidney transplant, making PKD the fourth leading cause of kidney failure. There is no cure for PKD.
About Samsara BioCapital
Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages approximately US$410 million in assets on behalf of endowments, foundations, and family offices. For more information, visit Samsara .
About the Roche Venture Fund
The Roche Venture Fund invests in early stage biotech and diagnostics companies to develop commercially successful innovative life science companies. Based in Basel, Switzerland with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of over 40 companies. For more information, please visit Roche Venture Fund .
About Medicxi
Medicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfil a clear unmet need. GSK, Johnson & Johnson Innovation – JJDC, Inc., Novartis and Verily (an Alphabet company) have invested in Medicxi funds.
For more information, please visit us at Medicxi and follow us on Twitter (@medicxi).
About Osage University Partners
OUP (Osage University Partners) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. OUP has partnered with over 100 universities, including 42 of the top 50 U.S. institutions by research expenditures, and has invested in over 100 of their spinouts. OUP is part of a family of investment funds within Osage Partners, which is based in Philadelphia, PA and manages in excess of $800 million. For more information, visit OUP .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200925005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incode Launches Incode Know Your Agent to Anchor AI Agent Trust in Verified Human Identity17.11.2026 15:14:00 CET | Press release
Businesses can now verify the human behind every AI agent acting on behalf of their customers and get access, control, and visibility over everything it does Incode, the identity platform trusted by more than 800 organizations, including nine of the top 10 US banks, eight of the top nine US telcos, and four of the top five global marketplaces, today launched Incode Know Your Agent, which ties every AI agent to a verified person and to the mandate that person set. With Incode Know Your Agent, businesses can get access, control, and visibility over every agent that acts on behalf of their customers. AI agents already act on behalf of people in banking, commerce, and everyday services. A fraudster’s agent can arrive with the same valid credentials as a customer’s, making it impossible for a business to tell them apart. AI agents are creating a new kind of economy, and fraud is growing inside it. Nearly seven in 10 Americans (69%) say they would let a bank’s AI assistant complete at least
Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 15:00:00 CET | Press release
Xsolla Expands Its Core Platform With Xsolla Quest Builder and Backpack to Help Developers and Brands Use Digital Items to Attract and Retain Players Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for pla
Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 15:00:00 CET | Press release
Trulioo customers can now verify identities and assess fraud risk in one integrated platform Trulioo and Bureau today announced a joint go-to-market partnership that adds Bureau’s device and behavioral intelligence, alongside its proprietary cross-business network graph intelligence for identifying connected fraud activity, to Trulioo’s global risk intelligence platform for fraud and financial crimes. Together, the companies are helping banks, fintechs, payments companies and marketplaces in APAC and the U.S. confirm who someone is and assess whether to trust them, all on one platform. AI is making fraud more complex and harder to detect, and organizations need stronger defenses to keep pace. Identity verification is only part of the picture; businesses also need to understand the risk behind every interaction, from onboarding throughout the customer journey. By partnering with Bureau, Trulioo is adding device and behavioral intelligence to its identity verification and risk signals, c
Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 15:00:00 CET | Press release
New purpose-built Pascari Space storage solutions deliver mission-specific reliability, resilience and customization for spacecraft, lunar and orbital data centers Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounti
Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises17.11.2026 15:00:00 CET | Press release
Turnkey system combines high-performance private AI inference, generative business intelligence and persistent enterprise storage for operational resilience Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of the Phison AI Data Platform (AIDP) with generative business intelligence (GenBI), a turnkey, sovereign AI system that will be showcased at Supercomputing 2026 (SC26) in booth #5413. Powered by Pascari aiDAPTIV ™ Cache Memory technology, Phison AIDP combines locally hosted AI models, integrated inference services, governed analytics and persistent enterprise storage to help organizations unlock business intelligence while maintaining control over their data, infrastructure and AI operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117045294/en/ Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
